{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:33:25Z","timestamp":1793424805793,"version":"4.5.0"},"reference-count":14,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 EY029594"],"award-info":[{"award-number":["R01 EY029594"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"award":["R01 EY029594"],"award-info":[{"award-number":["R01 EY029594"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background\/objective: Suprachoroidal triamcinolone acetonide (TA) was recently FDA-approved and is emerging as a new alternative to other local therapies for macular edema (ME) associated with noninfectious uveitis (NIU). The objective of this study is to evaluate the preliminary safety and efficacy of suprachoroidal TA in patients with refractory ME secondary to NIU. Methods: This was a retrospective review of a small cohort of patients with refractory ME secondary to NIU treated with suprachoroidal TA from November 2022 to October 2023. Results: Six eyes from five patients with refractory ME secondary to NIU were included in the study. The cohort included two females (40%), and the median age was 62 years (IQR = 8). Ophthalmic diagnoses included intermediate uveitis (n = 2; 40%), birdshot chorioretinopathy (n = 1; 20%), autoimmune retinopathy (n = 1; 20%), and panuveitis (n = 1; 20%). The median logMAR visual acuity was 0.7 (Snellen 20\/100) at baseline and improved to 0.3 (Snellen 20\/40) during follow-up visits at 1 month and 2\u20133 months. The median central subfield thickness (CST) was 690 \u03bcm at baseline and improved to 367.5 \u03bcm and 309 \u03bcm at the follow-up visits at 1 month and 2\u20133 months, respectively. The initial improvement in logMAR visual acuity and CST was less pronounced at follow-up visits at 6\u20137 months and 11\u201312 months. Conclusions: This study demonstrates the safety of suprachoroidal TA and efficacy signals, including improvement in visual acuity and ME at 3 months in patients with severe, refractory ME secondary to NIU.<\/jats:p>","DOI":"10.3390\/pharmaceutics18060675","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:58:38Z","timestamp":1780473518000},"page":"675","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Suprachoroidal Triamcinolone Acetonide for the Treatment of Refractory Macular Edema Secondary to Non-Infectious Uveitis"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8581-7428","authenticated-orcid":false,"given":"Bryant","family":"Menke","sequence":"first","affiliation":[{"name":"Truhlsen Eye Institute, Department of Ophthalmology, University of Nebraska Medical Center, Omaha, NE 68105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene H.","family":"Choo","sequence":"additional","affiliation":[{"name":"Truhlsen Eye Institute, Department of Ophthalmology, University of Nebraska Medical Center, Omaha, NE 68105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0828-8478","authenticated-orcid":false,"given":"Marc","family":"Ohlhausen","sequence":"additional","affiliation":[{"name":"Truhlsen Eye Institute, Department of Ophthalmology, University of Nebraska Medical Center, Omaha, NE 68105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9867-0909","authenticated-orcid":false,"given":"Timothy","family":"Kaftan","sequence":"additional","affiliation":[{"name":"Truhlsen Eye Institute, Department of Ophthalmology, University of Nebraska Medical Center, Omaha, NE 68105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Truhlsen Eye Institute, Department of Ophthalmology, University of Nebraska Medical Center, Omaha, NE 68105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Helget","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE 68198, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Erickson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE 68198, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Conrady","sequence":"additional","affiliation":[{"name":"Truhlsen Eye Institute, Department of Ophthalmology, University of Nebraska Medical Center, Omaha, NE 68105, USA"},{"name":"Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Yeh","sequence":"additional","affiliation":[{"name":"Truhlsen Eye Institute, Department of Ophthalmology, University of Nebraska Medical Center, Omaha, NE 68105, USA"},{"name":"Global Center for Health Security, University of Nebraska Medical Center, Omaha, NE 68198, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bjo.80.4.332","article-title":"Causes and frequency of blindness in patients with intraocular inflammatory disease","volume":"80","author":"Rothova","year":"1996","journal-title":"Br. J. Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.ophtha.2006.03.027","article-title":"Impact of Macular Edema on Visual Acuity in Uveitis","volume":"113","author":"Lardenoye","year":"2006","journal-title":"Ophthalmology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12348-021-00281-z","article-title":"Practice patterns regarding regional corticosteroid treatment in noninfectious Uveitis: A survey study","volume":"12","author":"McHarg","year":"2022","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.ophtha.2011.07.027","article-title":"Randomized Comparison of Systemic Anti-inflammatory Therapy Versus Fluocinolone Acetonide Implant for Intermediate, Posterior and Panuveitis: The Multicenter Uveitis Steroid Treatment Trial","volume":"118","author":"Kempen","year":"2011","journal-title":"Ophthalmology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ophtha.2018.08.021","article-title":"Periocular triamcinolone versus intravitreal triamcinolone versus intravitreal dexamethasone implant for the treatment of uveitic macular edema: The PeriOcular versus INTravitreal corticosteroids for uveitic macular edema (POINT) Trial","volume":"126","author":"Thorne","year":"2019","journal-title":"Ophthalmology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1167\/iovs.12-9872","article-title":"Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye","volume":"53","author":"Patel","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/24741264241246314","article-title":"Suprachoroidal Drug Delivery for Macular Edema Associated with Noninfectious Uveitis","volume":"8","author":"Huang","year":"2024","journal-title":"J. VitreoRetin. Dis."},{"key":"ref_8","unstructured":"Joszt, L. (2023, June 14). Xipere for Macular Edema Associated with Uveitis Launches in United States. AJMC. Available online: https:\/\/www.ajmc.com\/view\/xipere-for-macular-edema-associated-with-uveitis-launches-in-united-states."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3928\/1081-597X-19970701-16","article-title":"Proper method for calculating average visual acuity","volume":"13","author":"Holladay","year":"1997","journal-title":"J. Refract. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","article-title":"Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis","volume":"127","author":"Yeh","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ajo.2024.11.022","article-title":"Suprachoroidal Triamcinolone Acetonide for Noninfectious Uveitis: Real-World Impact on Clinical Outcomes","volume":"271","author":"Panse","year":"2025","journal-title":"Am. J. Ophthalmol."},{"key":"ref_13","first-page":"1139","article-title":"Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA)","volume":"106","author":"Khurana","year":"2021","journal-title":"Br. J. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/ceo.14175","article-title":"The standardisation of uveitis nomenclature (SUN) project","volume":"50","author":"Jabs","year":"2022","journal-title":"Clin. Exp. Ophthalmol."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/6\/675\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:15:19Z","timestamp":1780546519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/6\/675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":14,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["pharmaceutics18060675"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18060675","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]}}}